R. Valverde

发表

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results

E. Shpall, A. Younes, Y. Nieto, 2012, Leukemia & lymphoma.

Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

D. Podoloff, T. Manshouri, P. Mclaughlin, 2009 .

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

W. Erwin, H. Macapinlac, L. Medeiros, 2012, Blood.

26 Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin's disease (HD)

N. Ueno, B. Andersson, D. Couriel, 2003 .

Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.

Michael L. Wang, D. Podoloff, P. Mclaughlin, 2007 .

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

E. Jabbour, F. Turturro, U. Popat, 2013 .

Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

D. Podoloff, P. Mclaughlin, N. Ueno, 2006 .